apnea has been researched along with Cognition Disorders in 12 studies
Apnea: A transient absence of spontaneous respiration.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 8.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "This article examines the neurocognitive sequelae of repeated exposure to hypoxemia in apnea (breath-hold) divers." | 7.73 | Apnea diving: long-term neurocognitive sequelae of repeated hypoxemia. ( McFarland, K; Ridgway, L, 2006) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 4.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| " General findings include a significantly longer duration of unconsciousness in LE rats, but similar durations of apnea." | 3.75 | Strain differences in response to traumatic brain injury in Long-Evans compared to Sprague-Dawley rats. ( Hoane, MR; Quigley, A; Smith, DC; Tan, AA, 2009) |
| "Sleep apnea is one of the most deleterious disorders in children with adenotonsillar hypertrophy because it can induce hypoxemia of brain." | 3.73 | Neurocognitive abilities in children with adenotonsillar hypertrophy. ( Kowalska, B; Kurnatowski, P; Lapienis, M; Putyński, L, 2006) |
| "This article examines the neurocognitive sequelae of repeated exposure to hypoxemia in apnea (breath-hold) divers." | 3.73 | Apnea diving: long-term neurocognitive sequelae of repeated hypoxemia. ( McFarland, K; Ridgway, L, 2006) |
| " These performance deficits were only found in participants characterized by apneas." | 3.70 | Hyperventilation and attention: effects of hypocapnia on performance in a stroop task. ( Schippers, N; Stegen, K; Van de Woestijne, KP; Van den Bergh, O; Van Diest, I, 2000) |
| " Sleep-induced apnea may lead to abnormal movement and abnormal ambulation during sleep as well as hallucinations in the early morning." | 3.65 | Altered states of consciousness in disorders of daytime sleepiness. ( Billiard, M; Dement, WC; Guilleminault, C; Montplaisir, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khurana, S | 1 |
| Shivakumar, M | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Jayashree, P | 1 |
| Ramesh Bhat, Y | 1 |
| Lewis, LES | 1 |
| Tan, AA | 1 |
| Quigley, A | 1 |
| Smith, DC | 1 |
| Hoane, MR | 1 |
| Winckworth, LC | 1 |
| Powell, E | 1 |
| Schmidt, B | 2 |
| Anderson, PJ | 1 |
| Doyle, LW | 1 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Davis, PG | 1 |
| Tin, W | 1 |
| Moddemann, D | 1 |
| Solimano, A | 1 |
| Ohlsson, A | 1 |
| Barrington, KJ | 1 |
| Roberts, RS | 1 |
| Maitre, NL | 1 |
| Stark, AR | 1 |
| Kurnatowski, P | 1 |
| Putyński, L | 1 |
| Lapienis, M | 1 |
| Kowalska, B | 1 |
| Ridgway, L | 1 |
| McFarland, K | 1 |
| Van Diest, I | 1 |
| Stegen, K | 1 |
| Van de Woestijne, KP | 1 |
| Schippers, N | 1 |
| Van den Bergh, O | 1 |
| Sigsbee, B | 1 |
| Plum, R | 1 |
| Guilleminault, C | 1 |
| Billiard, M | 1 |
| Montplaisir, J | 1 |
| Dement, WC | 1 |
| Wright, BD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for apnea and Cognition Disorders
| Article | Year |
|---|---|
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities; | 2010 |
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I | 2005 |
The unresponsive patient.
Topics: Apnea; Blood-Brain Barrier; Brain Edema; Brain Stem; Cognition Disorders; Coma; Consciousness Disord | 1979 |
2 trials available for apnea and Cognition Disorders
| Article | Year |
|---|---|
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
7 other studies available for apnea and Cognition Disorders
| Article | Year |
|---|---|
Strain differences in response to traumatic brain injury in Long-Evans compared to Sprague-Dawley rats.
Topics: Animals; Animals, Outbred Strains; Apnea; Behavior, Animal; Brain; Brain Injuries; Cognition Disorde | 2009 |
Neuroprotection for premature infants?: another perspective on caffeine.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Female; Humans; Infant, Pre | 2012 |
Neurocognitive abilities in children with adenotonsillar hypertrophy.
Topics: Adenoids; Adolescent; Apnea; Brain; Child; Cognition Disorders; Female; Humans; Hypertrophy; Hypoxia | 2006 |
Apnea diving: long-term neurocognitive sequelae of repeated hypoxemia.
Topics: Adult; Apnea; Cognition Disorders; Diving; Female; Humans; Hypoxia; Male; Neuropsychological Tests; | 2006 |
Hyperventilation and attention: effects of hypocapnia on performance in a stroop task.
Topics: Adult; Apnea; Attention; Cognition Disorders; Humans; Hyperventilation; Hypocapnia; Reaction Time; S | 2000 |
Altered states of consciousness in disorders of daytime sleepiness.
Topics: Adult; Apnea; Automatism; Cataplexy; Cognition Disorders; Consciousness Disorders; Disorders of Exce | 1975 |
Diagnostic features of fat embolism--results in six cases.
Topics: Accidents, Traffic; Adult; Alkalosis; Apnea; Cognition Disorders; Humans; Hypoxia | 1971 |